Showing results (811-820 of 1,564) with videos related to
Sort By:
Pageof 157
Expert Review of Hematology|November 15, 2018
Venetoclax for the treatment of multiple myelomaIuliana Vaxman, M Hasib Sidiqi, Morie GertzExpert Review of Hematology|February 23, 2019
Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapyUtkarsh H Acharya, Tejaswini Dhawale, Seongseok Yun, et al.Expert Review of Hematology|February 19, 2019
Thrombophilia, risk factors and preventionElena Campello, Luca Spiezia, Angelo Adamo, et al.Expert Review of Hematology|February 17, 2021
The important role of intensive induction chemotherapy in the treatment of acute myeloid leukemiaTara L Lin, Livio PaganoExpert Review of Hematology|February 5, 2021
Real-world outcomes for the treatment of relapsed/refractory multiple myeloma patients with lenalidomide-dexamethasone combinations in a Latin American country. A retrospective cohort study from grupo argentino de mieloma múltiplePatricio Jose Duarte, Natalia Paola Schutz, Paola Ochoa, et al.Expert Review of Hematology|March 10, 2017
Targeting indolent non-Hodgkin lymphomaLori A Leslie, Alan P Skarbnik, Coleen Bejot, et al.Expert Review of Hematology|October 5, 2019
Blinatumomab: a novel therapy for the treatment of non-Hodgkin's lymphomaAli Bukhari, Seung Tae LeeExpert Review of Hematology|April 14, 2025
Advancements in targeting CD30 for lymphoma therapy: a historical perspective and future directionsHongju Zhang, Yuting Yan, Shuhua Yi, et al.Expert Review of Hematology|April 10, 2025
Novel drug combinations for newly diagnosed multiple myeloma: how can we improve on current regimens?Sofía Isabel Quezada-Ramírez, Luz Del Carmen Tarín-Arzaga, Andrés Gómez-De León, et al.Expert Review of Hematology|April 10, 2025
Circ_0035381 contributes to the progression of acute myeloid leukemia via regulating miR-186-5p/CDCA3 pathwayJinhuan Xu, Xi Ming, Jiaying Wu, et al.Pageof 157